The entries of “Technologies made in Vienna” are displayed in the project language.
Technologies from Vienna
Blue Sky Vaccines GmbH
NeoplasmsBlueSky Vaccines’ mission is to fully exploit the potential of virotherapy against cancer.
The company has developed delNS106, an influenza-based viral vector based on a deletion in its interferon (IFN) antagonist NS1.
Due to deletion in NS1, high levels of IFN are induced, which in turn lead to strong innate and adaptive immune responses capable of overcoming the immunosuppression created by cancers.
Kontakt Wirtschaftsagentur Wien
Information and networking are co-funded by the European Fund for regional development as part of the „IC3 Innovation by Co-Operation, Co-Creation and Community Building“ project. Additional information on the IWB/EFRE funding programme